EMAIL THIS PAGE TO A FRIEND

Neurology

Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam.


PMID 2011259

Abstract

The cognitive-enhancing effects of pramiracetam in animal models of learning and memory are characterized by an inverted U-shaped dose-response curve. We evaluated antidementia efficacy of this drug in 10 patients with probable Alzheimer's disease employing a 2-phase, placebo-controlled, enrichment-type trial design. Eight patients evidenced a best dose in the dose-finding phase, but in the subsequent replication phase only two again improved to a similar degree. PETs with fluorodeoxyglucose obtained in two individuals showed no definite change. Doses up to 4,000 mg pramiracetam are unlikely to confer symptomatic benefit to Alzheimer's disease patients.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SML0816 Pramiracetam, ≥98% (HPLC)
C14H27N3O2